Recent News

• 01.01.2026 - January 1, 2026 - January 8, 2026 : MASH-TAG 2026
• 10.07.2025 - October 7, 2025 - October 9, 2025 : Fierce Biotech Week
• 09.16.2025 - September 16, 2025 - September 17, 2025 : Obesity Science & Innovation 2025 Congress
• 09.08.2025 - September 8, 2025 - September 10, 2025 : H.C. Wainwright 26th Annual Global Investment Conference
• 09.03.2025 - September 3, 2025 - September 5, 2025 : Wells Fargo Healthcare Conference
• 08.26.2025 - MetaVia to Present at Upcoming Investor and Industry Conferences
• 08.07.2025 - MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.06.2025 - MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
• 08.04.2025 - MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241

Recent Filings

• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - 8-K Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 8-K Current report
• 08.06.2025 - 8-K Current report
• 08.06.2025 - EX-99.1 EX-99.1
• 08.04.2025 - EX-99.1 EX-99.1